HBOT is not an established treatment for asthma. To date, 0 randomized controlled trials support it, and no major guideline (GINA or the American Thoracic Society) lists it in asthma care. For people with asthma, HBOT is mainly a safety consideration rather than a therapy: air trapping and bronchospasm make an active asthma attack a reason to postpone treatment. If you have asthma and need HBOT for another condition, the question is whether it can be done safely, not whether it treats the asthma.
Can HBOT treat asthma?
No. Asthma involves chronic airway inflammation, bronchial hyperresponsiveness, and reversible bronchoconstriction. Because HBOT has anti-inflammatory effects in other tissues, suppressing pro-inflammatory cytokines and NF-kB signaling (Thom, 2011), the idea that it might calm airway inflammation sounds plausible.2 Whether those effects reach the airway epithelium and change asthma in any meaningful way has not been demonstrated. Asthma is one of many conditions people ask about; our guide to HBOT for chronic conditions puts the evidence for each in context.
What does research show about HBOT for asthma?
There are no randomized controlled trials of HBOT for asthma, and no peer-indexed controlled evidence that it improves asthma outcomes. Neither GINA (the Global Initiative for Asthma) nor the American Thoracic Society includes HBOT in asthma management.1 Asthma is not among the UHMS-approved HBOT indications,4 Medicare does not cover HBOT for it,5 and the FDA has warned consumers against unproven HBOT marketing.6 The evidence does not approach the standard required for a clinical recommendation, so any claim that HBOT treats asthma is unsupported.
randomized controlled trials support HBOT as a treatment for asthma
GINA 2025; UHMS indications
Is HBOT safe if you have asthma?
For stable, well-controlled asthma, HBOT for an approved indication is usually possible after a pulmonary evaluation. The risks concentrate in poorly controlled disease and during attacks, for three reasons.
Air trapping and barotrauma. As chamber pressure changes, trapped air in the lungs expands and contracts. In asthma with significant air trapping, mucus plugging, or active bronchospasm, that raises the risk of alveolar overdistension or rupture, including pneumothorax, during decompression (Camporesi, 2014).3 The risk is highest during acute exacerbations or in severe, poorly controlled asthma.
Oxygen-induced bronchospasm. A small proportion of people with asthma experience paradoxical bronchospasm on exposure to high oxygen concentrations. It is uncommon but worth raising with the hyperbaric physician, who may recommend a pre-session bronchodilator.
Never during an active attack. HBOT should not be pursued during an asthma exacerbation. Air trapping, bronchospasm, and a pressurized environment combine into an unsafe situation, and treatment for any indication should wait until asthma is stable. Acute bronchospasm in the chamber requires a slow, controlled depressurization rather than an immediate exit, which is why the team must know your asthma history in advance. For the general risk profile, see our HBOT side effects and contraindications guide.
An asthmatic patient with a diabetic wound, radiation injury, or other approved indication generally does not have to forgo HBOT. With a pulmonary evaluation confirming control and no significant air trapping (current spirometry), most stable asthmatics can receive HBOT safely, with a rescue inhaler on hand and communication between the pulmonologist and hyperbaric physician throughout the course. Obesity adds practical considerations (chamber fit and breathing mechanics) worth raising with the facility in advance.
What actually works for asthma?
Asthma has well-evidenced treatments that HBOT cannot approach. Inhaled corticosteroids are the cornerstone of chronic management, reducing inflammation, exacerbations, and mortality risk. Short-acting beta-agonists provide rescue bronchodilation. For severe allergic or eosinophilic asthma, biologics (omalizumab, mepolizumab, benralizumab, dupilumab) have changed outcomes for refractory patients. Allergen avoidance and trigger management underpin every asthma care plan (GINA, 2025).1
Standard asthma treatments vs HBOT
| Approach | Role in asthma | Evidence |
|---|---|---|
| Inhaled corticosteroids (ICS) | First-line controller | Strong, guideline standard |
| Short-acting beta-agonists (SABA) | Rescue bronchodilation | Strong, guideline standard |
| Biologics (anti-IgE, anti-eosinophil, anti-IL-4/13) | Severe or refractory asthma | Strong for selected patients |
| Trigger avoidance / immunotherapy | Reduce exposure and sensitivity | Established |
| HBOT | No established role | No RCTs; not in any guideline |
major asthma guidelines (GINA, American Thoracic Society) that include HBOT
GINA 2025
If you have severe or refractory asthma and want options beyond standard controllers, evaluation for biologic therapy should take priority over HBOT. If you are exploring non-standard routes, our HBOT alternatives overview is worth reading, and if your questions overlap with obstructive lung disease, see HBOT for COPD. The core recommendation is to optimize standard therapy with a pulmonologist before considering unproven adjuncts.
Frequently asked questions
I have mild, well-controlled asthma. Can I use HBOT for another condition?
Mild, well-controlled asthma is generally not a contraindication to HBOT for other approved indications. Disclose your asthma history to the hyperbaric physician, who will likely request recent spirometry and confirm your control status. Bring your rescue inhaler to sessions and discuss pre-treatment bronchodilator use with your treating team (Camporesi, 2014).
Can HBOT replace my asthma inhalers?
No. There is no evidence that HBOT reduces the need for asthma maintenance medications or can substitute for established therapies. Stopping or reducing asthma medication without physician guidance carries a real risk of exacerbation and serious harm.
What if I have both asthma and a condition HBOT is known to help?
This needs coordination between your pulmonologist and the hyperbaric physician. Most stable asthmatics can receive HBOT safely for an approved indication like radiation injury or a diabetic wound. The priority is confirming your asthma is well controlled and that spirometry shows no significant air trapping before starting.
Sources
- Global Initiative for Asthma. Global strategy for asthma management and prevention, 2025. ginasthma.org
- Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg. 2011;127(Suppl 1):131S-141S. DOI: 10.1097/PRS.0b013e3181fbe2bf
- Camporesi EM. Side effects of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41(3):253-257. PMID: 24984321
- Undersea and Hyperbaric Medical Society. Approved indications for hyperbaric oxygen therapy. uhms.org
- Centers for Medicare & Medicaid Services. National coverage determination for hyperbaric oxygen therapy, NCD 20.29. cms.gov
- U.S. Food and Drug Administration. Hyperbaric oxygen therapy: don’t be misled. 2021. fda.gov
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
